<p>SG Americas Securities LLC 在最近向證券交易委員會提交的文件中表示，在第二季度將其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的持股增加了 419.2%。該公司在季度內購買了額外的 93,367 股後，持有該製藥公司 115,640 股股票。根據其最近向證券交易委員會提交的文件，SG Americas Securities LLC 在 Vertex Pharmaceuticals 的持股價值為 51,483,000 美元。</p>
<ul>
<li>Royalty Pharma 如何在沒有生物技術最大風險的情況下盈利</li>
</ul>
<p>其他幾家大型投資者最近也對 VRTX 的持倉進行了調整。美國聯合服務汽車協會在第一季度購買了價值 2,933,000 美元的 Vertex Pharmaceuticals 新股份。Lee Johnson Capital Management LLC 在第二季度購買了價值約 721,000 美元的 Vertex Pharmaceuticals 新股份。新澤西州警察和消防員退休系統在第二季度將其在 Vertex Pharmaceuticals 的持股增加了 3.7%。新澤西州警察和消防員退休系統現在擁有 39,035 股該製藥公司的股票，價值 17,378,000 美元，此前在該期間內購買了額外的 1,393 股。Bailard Inc. 在第二季度將其在 Vertex Pharmaceuticals 的股份增加了 0.5%。Bailard Inc. 現在擁有 38,147 股該製藥公司的股票，價值 16,983,000 美元，此前在該期間內購買了額外的 200 股。最後，SteelPeak Wealth LLC 在第二季度收購了價值約 10,059,000 美元的 Vertex Pharmaceuticals 新股份。機構投資者和對沖基金持有該公司 90.96% 的股票。</p>
<p>獲取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
<h2>Vertex Pharmaceuticals 股票表現</h2>
<p>VRTX 股票在週五開盤價為 437.15 美元。該公司的市值為 1,109.1 億美元，市盈率為 31.25，貝塔值為 0.36。Vertex Pharmaceuticals Incorporated 的 52 周低點為 362.50 美元，52 周高點為 519.68 美元。該公司的 50 日移動平均價格為 408.04 美元，200 日移動平均價格為 427.84 美元。</p>
<ul>
<li>2025 年最佳生物技術股票</li>
</ul>
<p>Vertex Pharmaceuticals (NASDAQ:VRTX - 獲取免費報告) 最近在 11 月 3 日星期一發布了季度財報。該製藥公司報告季度每股收益 (EPS) 為 4.80 美元，超出分析師一致預期的 4.58 美元，超出幅度為 0.22 美元。Vertex Pharmaceuticals 的股本回報率為 23.91%，淨利潤率為 31.86%。該公司在季度內的收入為 30.8 億美元，而一致預期為 30.5 億美元。去年同期，該公司每股收益為 4.38 美元。Vertex Pharmaceuticals 的季度收入同比增長 11.0%。Vertex Pharmaceuticals 已設定其 2025 財年的每股收益指導。分析師預測 Vertex Pharmaceuticals Incorporated 今年將發佈 15.63 美元的每股收益。</p>
<h2>分析師設定新目標價</h2>
<p>幾位研究分析師對 VRTX 股票發佈了報告。瑞銀集團在 11 月 7 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 553.00 美元下調至 546.00 美元，並對該股票給予 &#34;買入&#34; 評級。摩根士丹利在 10 月 10 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 439.00 美元下調至 438.00 美元，並對該公司給予 &#34;持平&#34; 評級。華爾街 Zen 在 8 月 22 日的研究報告中將 Vertex Pharmaceuticals 的評級從 &#34;強烈買入&#34; 下調至 &#34;買入&#34;。Stifel Nicolaus 在 11 月 4 日的報告中將 Vertex Pharmaceuticals 的目標價從 455.00 美元下調至 445.00 美元，並對該公司給予 &#34;持有&#34; 評級。最後，Cantor Fitzgerald 在 8 月 5 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 535.00 美元下調至 485.00 美元，並對該股票給予 &#34;超配&#34; 評級。兩位研究分析師對該股票給予 &#34;強烈買入&#34; 評級，十六位給予 &#34;買入&#34; 評級，十一位給予 &#34;持有&#34; 評級。根據 MarketBeat.com 的數據，Vertex Pharmaceuticals 的平均評級為 &#34;適度買入&#34;，共識目標價為 491.95 美元。</p>
<ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
<p><strong>閲讀我們最新的 Vertex Pharmaceuticals 股票分析</strong></p>
<h2>Vertex Pharmaceuticals 公司簡介</h2>
<p>(免費報告)</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化 (CF) 的療法。它為至少 2 歲或以上的 F508del 突變患者提供 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者提供 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者提供 ORKAMBI；以及為 1 歲或以上的 CF 患者提供 KALYDECO。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票超過 Vertex Pharmaceuticals</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>MarketBeat 週迴顧 – 11/10 - 11/14</li>
<li>投資中的下調意味着什麼？</li>
<li>這三家被低估的科技巨頭準備反彈嗎？</li>
<li>2025 年有潛力上漲的兩隻 CRM 平台股票</li>
<li>如果你等待下跌，Micron Technology 可能會讓你錯過機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
<p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Vertex Pharmaceuticals 並不在名單上。</p>
<p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

福泰制藥

<p>SG Americas Securities LLC 在第二季度顯著增加了對 Vertex Pharmaceuticals 的持股，增幅達到 419.2%，目前持有 115,640 股，市值為 5148 萬美元。其他投資者也調整了在 Vertex 的持倉。該公司的股票開盤價為 437.15 美元，市值為 1109.1 億美元。分析師們對該股的評級意見不一，普遍目標價為 491.95 美元。Vertex 報告第三季度每股收益為 4.80 美元，超出預期，收入同比增長 11%</p>

<p>SG Americas Securities LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 419.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 115,640 shares of the pharmaceutical company's stock after buying an additional 93,367 shares during the quarter. SG Americas Securities LLC's holdings in Vertex Pharmaceuticals were worth $51,483,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>SG Americas Securities LLC 在最近向證券交易委員會提交的文件中表示，在第二季度將其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的持股增加了 419.2%。該公司在季度內購買了額外的 93,367 股後，持有該製藥公司 115,640 股股票。根據其最近向證券交易委員會提交的文件，SG Americas Securities LLC 在 Vertex Pharmaceuticals 的持股價值為 51,483,000 美元。</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在沒有生物技術最大風險的情況下盈利</li>
</ul>
</div><p>Several other large investors also recently made changes to their positions in VRTX. United Services Automobile Association bought a new stake in Vertex Pharmaceuticals during the first quarter valued at $2,933,000. Lee Johnson Capital Management LLC bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $721,000. Police &amp; Firemen s Retirement System of New Jersey increased its holdings in shares of Vertex Pharmaceuticals by 3.7% during the second quarter. Police &amp; Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company's stock valued at $17,378,000 after purchasing an additional 1,393 shares during the period. Bailard Inc. increased its stake in Vertex Pharmaceuticals by 0.5% during the 2nd quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company's stock valued at $16,983,000 after buying an additional 200 shares during the period. Finally, SteelPeak Wealth LLC acquired a new stake in Vertex Pharmaceuticals in the second quarter worth approximately $10,059,000. Institutional investors and hedge funds own 90.96% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家大型投資者最近也對 VRTX 的持倉進行了調整。美國聯合服務汽車協會在第一季度購買了價值 2,933,000 美元的 Vertex Pharmaceuticals 新股份。Lee Johnson Capital Management LLC 在第二季度購買了價值約 721,000 美元的 Vertex Pharmaceuticals 新股份。新澤西州警察和消防員退休系統在第二季度將其在 Vertex Pharmaceuticals 的持股增加了 3.7%。新澤西州警察和消防員退休系統現在擁有 39,035 股該製藥公司的股票，價值 17,378,000 美元，此前在該期間內購買了額外的 1,393 股。Bailard Inc. 在第二季度將其在 Vertex Pharmaceuticals 的股份增加了 0.5%。Bailard Inc. 現在擁有 38,147 股該製藥公司的股票，價值 16,983,000 美元，此前在該期間內購買了額外的 200 股。最後，SteelPeak Wealth LLC 在第二季度收購了價值約 10,059,000 美元的 Vertex Pharmaceuticals 新股份。機構投資者和對沖基金持有該公司 90.96% 的股票。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Vertex Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票表現</h2>
</div><p>Shares of VRTX stock opened at $437.15 on Friday. The company has a market capitalization of $110.91 billion, a P/E ratio of 31.25 and a beta of 0.36. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.68. The company's 50 day moving average price is $408.04 and its two-hundred day moving average price is $427.84.</p>
<div class="lb-trans"><p>VRTX 股票在週五開盤價為 437.15 美元。該公司的市值為 1,109.1 億美元，市盈率為 31.25，貝塔值為 0.36。Vertex Pharmaceuticals Incorporated 的 52 周低點為 362.50 美元，52 周高點為 519.68 美元。該公司的 50 日移動平均價格為 408.04 美元，200 日移動平均價格為 427.84 美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技術股票</li>
</ul>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the company earned $4.38 earnings per share. Vertex Pharmaceuticals's quarterly revenue was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals (NASDAQ:VRTX - 獲取免費報告) 最近在 11 月 3 日星期一發布了季度財報。該製藥公司報告季度每股收益 (EPS) 為 4.80 美元，超出分析師一致預期的 4.58 美元，超出幅度為 0.22 美元。Vertex Pharmaceuticals 的股本回報率為 23.91%，淨利潤率為 31.86%。該公司在季度內的收入為 30.8 億美元，而一致預期為 30.5 億美元。去年同期，該公司每股收益為 4.38 美元。Vertex Pharmaceuticals 的季度收入同比增長 11.0%。Vertex Pharmaceuticals 已設定其 2025 財年的每股收益指導。分析師預測 Vertex Pharmaceuticals Incorporated 今年將發佈 15.63 美元的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several research analysts have issued reports on VRTX shares. UBS Group decreased their price target on shares of Vertex Pharmaceuticals from $553.00 to $546.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, November 7th. Morgan Stanley reduced their price objective on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an &#34;equal weight&#34; rating for the company in a research note on Friday, October 10th. Wall Street Zen downgraded Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, August 22nd. Stifel Nicolaus cut their price target on Vertex Pharmaceuticals from $455.00 to $445.00 and set a &#34;hold&#34; rating for the company in a report on Tuesday, November 4th. Finally, Cantor Fitzgerald decreased their price target on Vertex Pharmaceuticals from $535.00 to $485.00 and set an &#34;overweight&#34; rating on the stock in a research note on Tuesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $491.95.</p>
<div class="lb-trans"><p>幾位研究分析師對 VRTX 股票發佈了報告。瑞銀集團在 11 月 7 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 553.00 美元下調至 546.00 美元，並對該股票給予 &#34;買入&#34; 評級。摩根士丹利在 10 月 10 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 439.00 美元下調至 438.00 美元，並對該公司給予 &#34;持平&#34; 評級。華爾街 Zen 在 8 月 22 日的研究報告中將 Vertex Pharmaceuticals 的評級從 &#34;強烈買入&#34; 下調至 &#34;買入&#34;。Stifel Nicolaus 在 11 月 4 日的報告中將 Vertex Pharmaceuticals 的目標價從 455.00 美元下調至 445.00 美元，並對該公司給予 &#34;持有&#34; 評級。最後，Cantor Fitzgerald 在 8 月 5 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 535.00 美元下調至 485.00 美元，並對該股票給予 &#34;超配&#34; 評級。兩位研究分析師對該股票給予 &#34;強烈買入&#34; 評級，十六位給予 &#34;買入&#34; 評級，十一位給予 &#34;持有&#34; 評級。根據 MarketBeat.com 的數據，Vertex Pharmaceuticals 的平均評級為 &#34;適度買入&#34;，共識目標價為 491.95 美元。</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on Vertex Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 Vertex Pharmaceuticals 股票分析</strong></p>
</div><h2>Vertex Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化 (CF) 的療法。它為至少 2 歲或以上的 F508del 突變患者提供 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者提供 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者提供 ORKAMBI；以及為 1 歲或以上的 CF 患者提供 KALYDECO。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>MarketBeat Week in Review – 11/10 - 11/14</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Are These 3 Oversold Tech Giants Ready to Rebound?</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>If You Wait for the Dip, Micron Technology Could Leave You Behind</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Vertex Pharmaceuticals</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>MarketBeat 週迴顧 – 11/10 - 11/14</li>
<li>投資中的下調意味着什麼？</li>
<li>這三家被低估的科技巨頭準備反彈嗎？</li>
<li>2025 年有潛力上漲的兩隻 CRM 平台股票</li>
<li>如果你等待下跌，Micron Technology 可能會讓你錯過機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Vertex Pharmaceuticals 並不在名單上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

SG Americas Securities LLC 增加了在福泰製藥公司 $VRTX 的持倉